An Open-label, Phase 1 Clinical Trial to Identify the Optimal Dose and Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Anti-tumor Efficacy of NOV1501 (ABL001) in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 03 Dec 2018
At a glance
- Drugs Asciminib (Primary)
- Indications Colon cancer; Gastric cancer; Gastrointestinal stromal tumours; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Sponsors ABL Bio
- 03 Dec 2018 Results presented in a TRIGR Therapeutics media release.
- 03 Dec 2018 According to a TRIGR Therapeutics media release, till date ABL Bio have enrolled 12 patients in this study.
- 29 Sep 2017 New trial record